Johnson & Johnson (NYSE:JNJ) today reported Q4 results that beat The Street on earnings but missed on revenue amid continued macroeconomic challenges. The company’s Pharmaceutical business saw sales grow 6.8%. Pharma growth drivers included: Darzalex (daratumumab), a biologic for the treatment of multiple myeloma; Stelara (ustekinumab), a biologic for the treatment of a number of…

Johnson & Johnson (NYSE:JNJ) today reported third-quarter results that topped the consensus forecast, with international pharma sales up 2.6% or 9.0% operationally. Drugs fueling growth include Stelara (ustekinumab), Darzalex (daratumumab), Tremfya (guselkumab), Xarelto (rivaroxaban) and Erleada (apalutamide). J&J licensed Darzelex from Genmab. The drug won FDA approval in 2015 for patients with previously treated multiple myeloma. Darzalex…

Johnson & Johnson (NYSE:JNJ) has announced that it will name its consumer health division “Kenvue.” Earlier this year, GSK (NYSE:GSK) made a similar move by naming its consumer healthcare segment “Haleon.” That moniker fuses the old English word ‘hale’ with the name “Leon.” The first word means ‘healthy’ while the second refers to “strength.” Haleon…

A new congressional report concluded that Emergent BioSolutions (NYSE:EBS) attempted to hide evidence related to quality problems before informing the FDA that 15 million COVID-19 vaccines were contaminated. Prepared for Rep. Carolyn Maloney (D-NY) and James E. Clyburn (D-SC), the report from the House and the Select Subcommittee on the Coronavirus Crisis scrutinizes the quality controls in…

On the heels of announcing a $99 million opioid settlement with West Virginia, Johnson & Johnson (NYSE:JNJ) has reached a similar deal worth $77 million with the state of Alabama. The agreement removes J&J from cases filed in the state. The agreement did not involve an admission of liability or wrongdoing. In January, J&J reached…

Johnson & Johnson (NYSE:JNJ) shares ticked up today on first-quarter results that were mixed compared to the consensus forecast. The New Brunswick, New Jersey-based company posted profits of $5.1 billion, or $1.93 per share, on sales of $23.4 billion in the first quarter for a 16.9% bottom-line slide on sales growth of nearly 5%. Get the…

Johnson & Johnson (NYSE:JNJ) has agreed to pay $99 million to put opioid-related claims in the State of West Virginia to bed.  The state has removed J&J from an ongoing trial in Kanawha County.  West Virginia’s attorney general, Patrick Morrisey, concluded that state’s decision not to join a nationwide settlement was worthwhile because the state received…

Medtech and pharma companies continue to support Ukraine relief efforts following Russia’s invasion. Previously, the World Health Organization announced that it was sending “essential medical supplies” to Ukraine — including its first shipment of 36 metric tons of supplies for trauma care and emergency surgery and other health supplies — to meet the needs of more than…

Johnson & Johnson (NYSE:JNJ) announced today that it completed an agreement for the manufacturing of its COVID-19 vaccine in Africa. The landmark agreement, made between Johnson & Johnson’s Janssen Pharmaceuticals and South Africa-based Aspen SA Operations, allows for the first COVID-19 vaccine to be manufactured and made available by an African company for people living…

Johnson & Johnson (NYSE:JNJ) has decided to temporarily suspend production of its COVID-19 vaccine in Leiden in the Netherlands to prioritize production of an investigational respiratory syncytial virus (RSV) vaccine, according to The New York Times. The plant will resume production of its COVID-19 vaccine in a matter of months, the paper reported. The company is…